A Patient and Caregiver's Guide: Recognizing and Responding to Residual Symptoms of Major Depressive Disorder (MDD)



MDD is a brain disorder that may affect your thoughts, feelings, behavior, and mood. It can be a recurrent, chronic, and seriously impairing disorder.²

The most common symptoms of MDD are depression and loss of interest, but each patient has a unique experience.²

Remission is the goal of depression treatment

However, only about 28% of individuals treated for MDD achieve remission following treatment with a single antidepressant.³

Inadequate response to antidepressant treatment is frequent (30-50%).¹¹

Approximately 50% of individuals with MDD have an inadequate response to antidepressant treatment.⁴ Patients not achieving remission typically suffer from troubling residual or lingering depressive symptoms.⁵

Over 80% of individuals with MDD continue to experience residual or lingering symptoms during the course of treatment.6

Common Residual MDD Symptoms:12



Why its important to treat residual depressive symptoms:

Increased risk of depressive relapse and suicidality^{7,8}

Poor social and work functioning⁹



Inadequately treated depression may lead to poor patient outcomes.¹⁰

Management of Residual MDD Symptoms:¹¹

1 Increase the antidepressant dose





Switch to combination strategies*

*Combination strategies can include medication (another antidepressant or non-antidepressant drug) or talk therapy.



Collaborating with Your Care Team

- Talk about ongoing symptoms that you may be having.
- Sometimes it is difficult to know if what you are experiencing is a symptom of mental illness. Tell your care team about any concerns you have.
- Ask your care team how you can manage symptoms in a way that works with your goals.

If you or someone you know is in crisis, call the Suicide Prevention Hotline/Lifeline at 1-800-273-TALK (8255) or text the Crisis Text line at 741-741.

References: 1. Brody et al 2018 NCHS Data Brief No. 303 2. World Health Organization. Fact Sheet on Depression. (2012) http://www.who.int/mediacentre/factsheets/fs369/en/index.html 3. Trivedi MH et al. Am J Psychiatry. 2006;163:28-40.
4. Sinyor M, Schaffer A, Levitt A: The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry. 2010, 55: 126-135.
5. Fava M. J Psychopharm. 2006;20(3):29-34.
6. Nierenberg AA et al. J Clin Psychiatry. 2010;48(2):291-296.
8. Dold et al. J Neuropsychopharmacol. 2018; 21(6): 539-549.
9. Romera I et al. Eur Psychiatry. 2010;25(1):58-65.
10. Mago et al., BMC Psychiatry. 2019;18(33).
11. Rafeyan, R. et al. The Jouranl of Clinical Psychiatry, 2020; 81(3): OT19037BR3.